CME Group director granted 645 shares

Mulchrone Patrick J reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Mulchrone Patrick J reported acquisition or exercise transactions in this Form 4 filing.

CME Group Inc. director Patrick J. Mulchrone received a grant of 645 shares of Class A common stock as part of the company’s annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. The grant price was $225.00 per share, and the shares are fully vested with no vesting conditions. After this award, he directly holds 29,130 Class A shares and has an additional 25,000 shares reported as indirectly owned by his spouse.

Insider Trade Summary

Grant/Award: 645 shares

Grant/Award 2 txns

Insider Mulchrone Patrick J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock Class A	645	$225.00	$145K
holding	Common Stock Class A	--	--	--

Holdings After Transaction: Common Stock Class A — 29,130 shares (Direct); Common Stock Class A — 25,000 shares (Indirect, by Spouse)

Footnotes (1)

1. F1. Represents a grant of fully vested shares of Class A Common Stock issued to the Reporting Person as part of the Issuer's annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. These shares are not subject to any vesting conditions.

Key Figures

Equity grant size: 645 shares Grant price per share: $225.00 per share Direct holdings after grant: 29,130 shares +1 more

4 metrics

Equity grant size 645 shares Class A common stock grant to director on June 25, 2026

Grant price per share $225.00 per share Price used for the 645-share director equity grant

Direct holdings after grant 29,130 shares Class A common stock directly owned by Patrick J. Mulchrone

Indirect spouse holdings 25,000 shares Class A common stock reported as owned indirectly by spouse

Key Terms

annual equity compensation program, CME Group Director Stock Plan, fully vested shares, non-employee directors

4 terms

annual equity compensation program financial

"Represents a grant of fully vested shares ... as part of the Issuer's annual equity compensation program for non-employee directors"

CME Group Director Stock Plan financial

"issued to the Reporting Person as part of the Issuer's annual equity compensation program ... under the CME Group Director Stock Plan"

fully vested shares financial

"Represents a grant of fully vested shares of Class A Common Stock"

non-employee directors financial

"annual equity compensation program for non-employee directors under the CME Group Director Stock Plan"

Non-employee directors are board members who do not work for the company as salaried employees and usually do not hold day-to-day management roles. They act like outside referees or independent coaches, providing oversight, asking tough questions, and protecting shareholders’ interests; investors care because these directors help ensure management is accountable, reduce conflicts of interest, and influence decisions that affect company strategy and long-term value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CME (CME) report for Patrick J. Mulchrone?

CME Group reported that director Patrick J. Mulchrone received a grant of 645 Class A common shares. The shares were issued as part of the company’s annual equity compensation program for non-employee directors under the CME Group Director Stock Plan.

At what price were the new CME (CME) shares granted to the director?

The 645 Class A shares granted to director Patrick J. Mulchrone were priced at $225.00 per share. This reflects the grant valuation for the equity award under CME Group’s director stock compensation program, rather than an open-market purchase or sale.

How many CME (CME) shares does Patrick J. Mulchrone now hold directly?

Following the equity grant, Patrick J. Mulchrone directly holds 29,130 shares of CME Group Class A common stock. This total includes the 645 fully vested shares granted as part of the annual equity compensation program for non-employee directors.

What does indirect ownership by spouse mean in this CME (CME) Form 4?

The Form 4 shows 25,000 CME Group Class A shares held indirectly "by Spouse." This indicates shares are reported as beneficially owned through the director’s spouse, separate from the 29,130 shares that he holds directly in his own name.

Are the CME (CME) director’s newly granted shares subject to vesting?

The 645 Class A shares granted to Patrick J. Mulchrone are fully vested and not subject to vesting conditions. According to the footnote, they were issued under the CME Group Director Stock Plan as part of the annual equity compensation program for non-employee directors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:22 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mulchrone Patrick J

(Last) (First) (Middle)

20 S. WACKER DR.

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock Class A	06/25/2026		A(1)		645	A	$225	29,130	D
Common Stock Class A								25,000	I	by Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of fully vested shares of Class A Common Stock issued to the Reporting Person as part of the Issuer's annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. These shares are not subject to any vesting conditions.

Remarks:

	/s/ Elizabeth Hensen, as Attorney-in-Fact for Patrick J. Mulchrone	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)